Custopharm operates in the pharmaceutical industry, focusing on the development and commercialization of generic injectable products. The company primarily serves healthcare providers and pharmaceutical companies that require high-quality, cost-effective alternatives to branded injectable medications. Custopharm's business model revolves around obtaining FDA approvals for complex, high-barrier generic products, which allows them to be first to market. This strategy not only ensures a competitive edge but also maximizes revenue potential. The company generates income through the sale of its generic injectable products and through strategic partnerships and acquisitions. Custopharm is actively expanding its operations and enhancing its scientific personnel to further solidify its market position. The company is also seeking new product and partnership opportunities to broaden its portfolio and capabilities.

Keywords: generic injectables, FDA approvals, pharmaceutical development, strategic partnerships, cost-effective alternatives, healthcare providers, market expansion, scientific personnel, product acquisitions, regulatory services.